Limits...
DNA-Based Nanobiosensors as an Emerging Platform for Detection of Disease.

Abu-Salah KM, Zourob MM, Mouffouk F, Alrokayan SA, Alaamery MA, Ansari AA - Sensors (Basel) (2015)

Bottom Line: The goal of nanodiagnostics is to provide more accurate tools for earlier diagnosis, to reduce cost and to simplify healthcare delivery of effective and personalized medicine, especially with regard to chronic diseases (e.g., diabetes and cardiovascular diseases) that have high healthcare costs.Up-to-date results suggest that DNA-based nanobiosensors could be used effectively to provide simple, fast, cost-effective, sensitive and specific detection of some genetic, cancer, and infectious diseases.We discuss recent trends and applications of new strategies for DNA-based nanobiosensors, and emphasize the challenges in translating basic research to the clinical laboratory.

View Article: PubMed Central - PubMed

Affiliation: Research Chair for Medical Applications of Nanomaterials, King Saud University, PO Box 2454, Riyadh 11451, Saudi Arabia. k_abusalah@hotmail.com.

ABSTRACT
Detection of disease at an early stage is one of the biggest challenges in medicine. Different disciplines of science are working together in this regard. The goal of nanodiagnostics is to provide more accurate tools for earlier diagnosis, to reduce cost and to simplify healthcare delivery of effective and personalized medicine, especially with regard to chronic diseases (e.g., diabetes and cardiovascular diseases) that have high healthcare costs. Up-to-date results suggest that DNA-based nanobiosensors could be used effectively to provide simple, fast, cost-effective, sensitive and specific detection of some genetic, cancer, and infectious diseases. In addition, they could potentially be used as a platform to detect immunodeficiency, and neurological and other diseases. This review examines different types of DNA-based nanobiosensors, the basic principles upon which they are based and their advantages and potential in diagnosis of acute and chronic diseases. We discuss recent trends and applications of new strategies for DNA-based nanobiosensors, and emphasize the challenges in translating basic research to the clinical laboratory.

No MeSH data available.


Related in: MedlinePlus

Schematic illustration of preparation of the nanostructured film of mixed (DNA-nanomaterial/SPE) [113].
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4507582&req=5

sensors-15-14539-f005: Schematic illustration of preparation of the nanostructured film of mixed (DNA-nanomaterial/SPE) [113].

Mentions: A novel electrochemical biosensor for berberine monitoring based on MWCNTs immobilized with ssDNA on screen-printed carbon electrodes (SPE) has been reported by Ovadecova et al. [113]. The DNA-(GNP–MWNT-SDS)/SPE electrode has been used for detection of effect of berberine on DNA from cancer cells. The electrode was prepared by dispersion of MWCNTs in dimethylformamide (DMF) or a colloidal gold nanoparticles (GNP) in phosphate buffer solution (PBS), solution of sodium dodecyl sulfate (SDS), and a DNA aqueous solution followed by casting of the prepared ssDNA/MWCNTs on the electrode (Figure 5). Ovadecova et al. [113] have also shown the synergy effect between CNTs and redox marker Co[(phen)3]3+ with the significant improvement of redox activity of guanine moiety. The obtained results for DNA-(GNP–MWNT-SDS)/SPE demostrated a 104-fold increase in the sensitivity toward berberine compared with only DNA modified electrodes. Based on this result, the authors contributed the observed remarkable enhancement in the detection sensitivity to the significant increase in the surface area of the electrode caused by the presence of DNA-(GNP–MWNT-SDS)/SPE in the composite, thus allowing a higher density of boronic acid groups to be available for dopamine binding. The resulting biosensor is effective for the detection of berberine effect on human cancer cell line (U937), which had a very strong effect on the structural stability of DNA at relatively low concentrations. Non-cancer cells were affected only at relatively high concentrations of berberine (75 and 50 μg·mL−1) [113].


DNA-Based Nanobiosensors as an Emerging Platform for Detection of Disease.

Abu-Salah KM, Zourob MM, Mouffouk F, Alrokayan SA, Alaamery MA, Ansari AA - Sensors (Basel) (2015)

Schematic illustration of preparation of the nanostructured film of mixed (DNA-nanomaterial/SPE) [113].
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4507582&req=5

sensors-15-14539-f005: Schematic illustration of preparation of the nanostructured film of mixed (DNA-nanomaterial/SPE) [113].
Mentions: A novel electrochemical biosensor for berberine monitoring based on MWCNTs immobilized with ssDNA on screen-printed carbon electrodes (SPE) has been reported by Ovadecova et al. [113]. The DNA-(GNP–MWNT-SDS)/SPE electrode has been used for detection of effect of berberine on DNA from cancer cells. The electrode was prepared by dispersion of MWCNTs in dimethylformamide (DMF) or a colloidal gold nanoparticles (GNP) in phosphate buffer solution (PBS), solution of sodium dodecyl sulfate (SDS), and a DNA aqueous solution followed by casting of the prepared ssDNA/MWCNTs on the electrode (Figure 5). Ovadecova et al. [113] have also shown the synergy effect between CNTs and redox marker Co[(phen)3]3+ with the significant improvement of redox activity of guanine moiety. The obtained results for DNA-(GNP–MWNT-SDS)/SPE demostrated a 104-fold increase in the sensitivity toward berberine compared with only DNA modified electrodes. Based on this result, the authors contributed the observed remarkable enhancement in the detection sensitivity to the significant increase in the surface area of the electrode caused by the presence of DNA-(GNP–MWNT-SDS)/SPE in the composite, thus allowing a higher density of boronic acid groups to be available for dopamine binding. The resulting biosensor is effective for the detection of berberine effect on human cancer cell line (U937), which had a very strong effect on the structural stability of DNA at relatively low concentrations. Non-cancer cells were affected only at relatively high concentrations of berberine (75 and 50 μg·mL−1) [113].

Bottom Line: The goal of nanodiagnostics is to provide more accurate tools for earlier diagnosis, to reduce cost and to simplify healthcare delivery of effective and personalized medicine, especially with regard to chronic diseases (e.g., diabetes and cardiovascular diseases) that have high healthcare costs.Up-to-date results suggest that DNA-based nanobiosensors could be used effectively to provide simple, fast, cost-effective, sensitive and specific detection of some genetic, cancer, and infectious diseases.We discuss recent trends and applications of new strategies for DNA-based nanobiosensors, and emphasize the challenges in translating basic research to the clinical laboratory.

View Article: PubMed Central - PubMed

Affiliation: Research Chair for Medical Applications of Nanomaterials, King Saud University, PO Box 2454, Riyadh 11451, Saudi Arabia. k_abusalah@hotmail.com.

ABSTRACT
Detection of disease at an early stage is one of the biggest challenges in medicine. Different disciplines of science are working together in this regard. The goal of nanodiagnostics is to provide more accurate tools for earlier diagnosis, to reduce cost and to simplify healthcare delivery of effective and personalized medicine, especially with regard to chronic diseases (e.g., diabetes and cardiovascular diseases) that have high healthcare costs. Up-to-date results suggest that DNA-based nanobiosensors could be used effectively to provide simple, fast, cost-effective, sensitive and specific detection of some genetic, cancer, and infectious diseases. In addition, they could potentially be used as a platform to detect immunodeficiency, and neurological and other diseases. This review examines different types of DNA-based nanobiosensors, the basic principles upon which they are based and their advantages and potential in diagnosis of acute and chronic diseases. We discuss recent trends and applications of new strategies for DNA-based nanobiosensors, and emphasize the challenges in translating basic research to the clinical laboratory.

No MeSH data available.


Related in: MedlinePlus